Relapse risk after discontinuation of risperidone in Alzheimer's disease.
about
Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaPharmacological management of behavioral symptoms associated with dementiaThe long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's diseaseDiscontinuing inappropriate medication in nursing home residents (DIM-NHR Study): protocol of a cluster randomised controlled trialThe feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.Pharmacotherapy of neuropsychiatric symptoms of dementiaAntipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.The development and testing of the quality use of medications in dementia (QUM-D): a tool for quality prescribing for behavioral and psychological symptoms of dementia (BPSD).A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practiceDoubly blind: a systematic review of gender in randomised controlled trials.Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.Halting Antipsychotic Use in Long-Term care (HALT): a single-arm longitudinal study aiming to reduce inappropriate antipsychotic use in long-term care residents with behavioral and psychological symptoms of dementia.Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.Management of Behavioral and Psychological Symptoms of Dementia.Antipsychotic drug use and associations with neuropsychiatric symptoms in persons with impaired cognition: a cross-sectional study.Treatment changes among older patients with dementia treated with antipsychotics.Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.Antipsychotic Use in Dementia.Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms.A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms.[Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice].Antipsychotic drugs for psychosis and agitation in dementia: efficacy, safety, and a possible noradrenergic mechanism of action.Use of antipsychotics and benzodiazepines for dementia: Time for action? What will be required before global de-prescribing?Systemic approach to behavioural and psychological symptoms of dementia in residential aged care facilities.Neuroleptic equivalent dose differences and behavioral and psychological symptoms of dementia.Neuropsychiatric symptoms of dementia: consent, quality of life, and dignity.[Advance directive of probands in pharmaceutical research : A medical ethics discussion].Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder
P2860
Q24198248-3B7A96D9-32D4-4F41-8123-9E3237F2CCCAQ28081955-C687ECD7-1C0C-4844-A19A-133A50DD560DQ30413790-5518B7A8-830E-4F5E-96D7-1E54BA3E1274Q34327516-930A7402-C174-4C64-B637-4EDE3CFF4F8DQ34522113-A6649A6B-B9A3-44FD-A24F-F9A7689B768AQ35229781-D470ABC0-5115-4CEA-9C11-1F98C4E1285FQ35630897-AAE99874-9A8D-4A96-AA69-EADB9E81E6BBQ35848943-CF41FA53-C1B9-409D-9C9D-BF588A1D42EDQ36091476-E8506D55-BAD1-4024-92CD-D015AE71DEE8Q36805845-870F3F2A-77C9-4D55-A578-4BA9AC71295CQ38364828-2676861E-4693-4B70-9506-A43E63547A62Q38590192-89553F67-F22F-4591-9CD0-64312BDCD37AQ38925563-81122267-8C20-4CF3-A022-02ADE7394845Q39163974-C5F6F9E1-8C10-4AF6-B905-C04384991ACBQ39209888-7CBE0E12-7359-45CC-AA92-F1F07C7687F7Q39684580-12444198-DDFF-41C1-B20E-2AC5625CEF84Q41247718-3D52B46C-8C5E-4B63-99EC-E4153A14F563Q41279177-3A2B808E-6835-49E6-BB3F-006A773F2C09Q41827089-F394AAF0-F195-42B2-BDB6-0F1AC33E12D5Q47737322-1C98DEFD-3BBC-4E07-AB23-B74B043782BBQ48124606-9145677C-ED99-4710-9CE6-ACC0F3168A70Q48310320-3F0C5458-B72F-4D6E-84A5-130B0AC4AFA4Q48319473-C8A6868E-F77A-47AD-B1B4-BBA17B2A92ADQ48358619-F8B812C8-3CFA-4D70-9FB0-4B5C5E77BBEAQ50698782-F2A1D7F2-4A02-42E2-9EEC-DA222FC04474Q50724211-0A8AF884-931E-4109-87AD-BE98136DD35BQ52933114-41E78B61-CA71-4059-9585-987C70EBB0EAQ53391968-75C5DBA4-7B93-4AF3-AA72-A07BE504E5DDQ58567918-496DFAF5-5743-431E-B52C-5E99B1BF2BEE
P2860
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@ast
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@en
type
label
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@ast
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@en
prefLabel
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@ast
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@en
P2093
P2860
P356
P1476
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
@en
P2093
Bruce Levin
Corbett Schimming
D P Devanand
Danilo de la Pena
David L Sultzer
Gregory H Pelton
Howard F Andrews
Jacobo Mintzer
Sanjay Gupta
Susan K Schultz
P2860
P304
P356
10.1056/NEJMOA1114058
P407
P577
2012-10-01T00:00:00Z